**Editorial comments:**  
  
1. Line 2: Drug delivery has not been shown or demonstrated in this article. Please edit the title to best represent the protocol and results you are showing here.

Response: The title has been changed from “delivery” to “formulation” to represent our protocol and results.

2. Line 79,183,188,190 and 202: References?

Response: I added references #14, #24, #14 and 15, #14 and #15 on line 79, 183, 188, 190, and 202 respectively.

14 Yang, H., Fung, S. Y. & Liu, M. Programming the cellular uptake of physiologically stable peptide-gold nanoparticle hybrids with single amino acids. *Angewandte Chemie International Edition.* **50** (41), 9643-9646, doi:10.1002/anie.201102911, (2011).

15 Lee, D. *et al.* Effective delivery of a rationally designed intracellular peptide drug with gold nanoparticle-peptide hybrids. *Nanoscale.* **7** (29), 12356-12360, doi:10.1039/c5nr02377g, (2015).

24 Kimling, J. *et al.* Turkevich method for gold nanoparticle synthesis revisited. *The Journal of Physical Chemistry B.* **110** (32), 15700-15707, doi:10.1021/jp061667w, (2006).

3. Line 79: This was not tested in this article. Please avoid making claims that are unsupported.

4. Line 87: I’m not sure why you say this when you did not demonstrate any in vivo applications in here.

Response: The objective of JoVE is to present the protocols. We have now added clear references to declare previous work. We clearly stated that this article is for the formulation protocol. I hope this will be acceptable by the reviewer.

5. Line 97: I edited for clarity, please verify If this is correct.

Response: Thanks. It is correct.

6. Line 108: Mention sonicator frequency and amplitude (available in the manufacturer datasheet)

Response: Its frequency is 40MHz. Our device does not have a parameter to change intensity. Its datasheet does not mention its amplitude. I added this information into the text.

7. Line 122: In the introduction you call this GNP-PKCi, please be consistent in the terminology!

Response: I now call our product as GNP/PKCi.

8. Line 143: How do you decide this? Please explain.

Response: I explained it on a note below。

Note: The GNP pellet contains 6.3x 1011 particles. For example, we administrated 1.3x 1012 particles in 500 *µ*L of 0.9% NaCl to treat rat IR injury. In that situation, we added 232 *µ*L of 0.9% NaCl to each of three pellets. After pooled them together, we collected 500 *µ*L of GNP/PKCi solution.

9. Line 154：This is incorrect, OD measurement does not reveal any about the biophysics of the GNP/PKCi hybrid.

Response: I have changed it to “solubility of”

10. Line157: Can you add additional assessment steps? Eg. Those you have mentioned here: <http://www.rsc.org/suppdata/c5/nr/c5nr02377g/c5nr02377g1.pdf>. They don’t need to be detailed, you can mention them and cite references.

11. Line 159: 1 test on 3 samples is really insufficient for the results section of a scientific publication. Please add additional figures and results discussion to discuss the assessments, in vivo tests, drug delivery, cellular uptake, microscopy you performed etc.

Response: We have changed the title of the paper as “formulation” only. Therefore, we do not need to refer too much on the previous publication.

12.Line164: Can you show a curve?

13. Line170: What is the reference that you are comparing these curves against, i.e. how do you know this is good quality?

14. Line171: What is an example of bad preparation?

Response: I now answer to all these questions. I added new figures to show how we know good or bad quality.